Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Cellectar Biosciences Inc
CLRBCurrent price
2.37 USD
+0.035 USD (+1.50%)
Last closed
2.34 USD
Company
www.cellectar.com
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
90 339 224 USD
Yield for 12 month
+25.13 %
1Y
3Y
5Y
10Y
15Y
CLRB
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey. Address: 100 Campus Drive, Florham Park, NJ, United States, 07932
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
12.6 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
+330 366 USD
Current Year
-192 375 USD
Last Year
-238 867 USD
Current Quarter
-88 490 USD
Last Quarter
+260 406 USD
Key Figures CLRB
1 year
3 years
5 years
10 years
EBITDA
-42 018 520 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-91.47 %
PEG Ratio
–
Return On Equity TTM
-304.38 %
Wall Street Target Price
12.6 USD
Revenue TTM
–
Book Value
0.27 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-3.09 USD
Diluted Eps TTM
-3.09 USD
Most Recent Quarter
I 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics CLRB
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CLRB
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:10
Payout Ratio
–
Last Split Date
22.07.2022
Dividend Date
17.07.2018
Stock Valuation CLRB
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
-2.8446
Price Book MRQ
2.6673
Financials CLRB
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators CLRB
For 52 weeks
1.56 USD
4.45 USD
50 Day MA
2.87 USD
Shares Short Prior Month
2 367 004
200 Day MA
3.06 USD
Short Ratio
4.33
Shares Short
2 273 178
Short Percent
7.2 %
BeatStart